Malin Inghammar
1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
COVID-19 vaccine uptake in Skåne county, Sweden, in relation to individual-level and area-level sociodemographic factors: a register-based cross-sectional analysis
(
- Contribution to journal › Article
-
Mark
Previous SARS-CoV-2 infections and their impact on the protection from reinfection during the Omicron BA.5 wave – a nested case-control study among vaccinated adults in Sweden
(
- Contribution to journal › Article
- 2023
-
Mark
Prognosis after Intensive Care for COPD Exacerbation in Relation to Long-Term Oxygen Therapy : A Nationwide Cohort Study
(
- Contribution to journal › Article
-
Mark
Improved identification of Streptococcus bovis-Streptococcus equinus-complex species and subspecies by MALDI-TOF MS using a novel library
(
- Contribution to journal › Article
-
Mark
Influenza A subtype H3N2 is associated with an increased risk of hospital dissemination – an observational study over six influenza seasons
(
- Contribution to journal › Article
-
Mark
Waning protection after vaccination and prior infection against COVID-19-related mortality over 18 months
(
- Contribution to journal › Article
- 2022
-
Mark
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden
(
- Contribution to journal › Article
-
Mark
A retrospective cohort study of the effect of SARS-CoV-2 point of care rapid RT-PCR at the Emergency Department on targeted admission
(
- Contribution to journal › Article
-
Mark
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022
2022) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 27(18).(
- Contribution to journal › Article
-
Mark
COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants: surveillance results from southern Sweden, December 2021 to March 2022
2022)(
- Working paper/Preprint › Preprint in preprint archive